Achaogen earns $12M award for next-gen antibiotics; Endo acquires Somerset for $190M
→ Antibacterial R&D accelerator CARB-X has granted Achaogen $AKAO an award worth up to $12 million to fuel its early-stage programs in for multi-drug resistant gram-negative infections. With an initial payment of $2.4 million, the South San Francisco biotech will focus on developing next-gen versions of a common class of antibiotics called aminoglycoside, aiming to overcome current resistance mechanisms. The partners are particularly keen on the prospect of treating Enterobacteriaceae, P. aeruginosa and A. baumannii, all “priority 1 critical pathogens” as recognized by the WHO. “The projects in the Powered by CARB-X portfolio are in the early stages of research, but if successful, these innovative projects hold great potential to treat serious infections and fight against the rise of drug-resistant bacteria,” said Kevin Outterson, executive director of CARB-X (formerly known as the Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator).
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.